���重受体激动剂的分子设计 — Deep Dive

By Editorial Desk · published 2025-07-28 · last reviewed 2025-08-24 · Guide

Everything below concerns phase 2 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-08-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

三重受体激动剂的分子设计

该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。

三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。

Retatrutide Background and Receptor Activity

Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.

Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.

Retatrutide at a glance

Trial Endpoints and Interpretation

Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.

Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.

Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.

Related pages on this site

• Optimized guide
• Adaptive briefing
• Automated notes
• Portable review
• Sustainable workbook
• Measured summary
• Measured update
• Connected notes

瑞他鲁肽开发背景

开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。

与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。

瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。

Notes from published material

==== Naked mRNA injection ==== Naked mRNA injection means that the delivery of the vaccine is only done in a buffer solution. This mode of mRNA uptake has been known since the 1990s. The first worldwide clinical studies used intradermal injections of naked mRNA for vaccination. A variety of methods have been used to deliver naked mRNA, such as subcutaneous, intravenous, and intratumoral injections. Although naked mRNA delivery causes an immune response, the effect is relatively weak, and after injection the mRNA is often rapidly degraded.

Although this can result in high prolactin levels in some assay tests, macroprolactin is biologically inactive and will not cause symptoms typical of hyperprolactinemia. In those who are asymptomatic or without obvious causes of hyperprolactinemia, macroprolactin should be assessed and ruled out. However, in patients with abnormally high levels of serum prolactin, false negative results that indicates a low level of prolactin may occur; this occurrence is due to a phenomenon called the "Hook effect". Antigen tests such as the pregnancy test shows positive line via the formation of a sandwich immune complex that allows the positive line to be visible, in the occurrence of Hook Effect, large amounts of analyte exists in the solution which saturates the antibodies, preventing normal binding and formation of the sandwich immune complex therefore showing a weak positive line. In the case of diagnosing hyperprolactinaemia, a weak positive line can often lead to a false negative result and increase the risk of misdiagnosis of the condition or a potential pituitary adenomas. If Hook Effect is suspected in the patient diagnosis, serial dilution of the analyte until the concentration of prolactin falls within the assay's analytical measurements is suggested. Ruling out the possibilities of false negatives is important to ensure patients receive necessary care for their conditions.

=== House of Tirol === Albert I (–1078), Count of Eurasburg Albert II (1078–1101), maybe son of Albert I Albert III (1101–1165), son of Albert II Berthold I (1165–1180), son of Albert II Berthold II (1180–1181), son of Berthold I Henry I (1181–1202), son of Berthold I Albert IV (1202–1253), son of Henry I Male line extinct.

=== Articles === Rosen, DR; Siddique, T; Patterson, D; Figlewicz, DA; Sapp, P; Hentati, A; Donaldson, D; Goto, J; O'Regan, JP; Deng, HX; et al. (1993). "Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis". Nature. 364 (6435): 362. Bibcode:1993Natur.364..362R. doi:10.1038/364362c0. PMID 8332197. Gusella, JF; Wexler, NS; Conneally, PM; Naylor, SL; Anderson, MA; Tanzi, RE; Watkins, PC; Ottina, K; Wallace, MR; Sakaguchi, AY; Young, AB; Shoulson, I; Bonilla, E; Martin, JB (1983). "A polymorphic DNA marker genetically linked to Huntington's Disease". Nature. 306 (5940): 234–238. Bibcode:1983Natur.306..234G. doi:10.1038/306234a0. PMID 6316146. S2CID 4320711. Tanzi, RE; Gusella, JF; Watkins, PC; Bruns, GAP; St; George-Hyslop, PH; Van Keuren, ML; Patterson, D; Pagan, S; Kurnit, DM; Neve, RL. (1987). "The amyloid beta protein gene: cDNA cloning, mRNA distribution, and genetic linkage near the Alzheimer locus". Science. 235 (4791): 880–884. Bibcode:1987Sci...235..880T. doi:10.1126/science.2949367. PMID 2949367. Tanzi, RE; McClatchey, AI; Lamperti, ED; V-Komaroff, L; Gusella, JF; Neve, R (1988). "Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease". Nature. 331 (6156): 528–530. Bibcode:1988Natur.331..528T. doi:10.1038/331528a0. PMID 2893290. S2CID 4277294.

Retrieved 26 September 2021 – via Google Books. Jones, Colin (1994). The Cambridge Illustrated History of France. Cambridge University Press. ISBN 978-0-521-66992-4. Jones, Maldwyn Allen (1992). Boorstin, Daniel J. (ed.). American Immigration. University of Chicago Press. ISBN 978-0-226-40633-6. Kagan, Frederick (2007). The End of the Old Order: Napoleon and Europe, 1801–1805. Hachette Books. ISBN 978-0-306-81645-1. Keeling, Drew (1999). "The Transportation Revolution and Transatlantic Migration". Research in Economic History. 19. Keeling, Drew (1 January 2007). "Transport Capacity Management and Transatlantic Migration, 1900–1914". Research in Economic History. 25. Emerald Group Publishing Limited: 225–283. doi:10.1016/s0363-3268(07)25005-0. ISBN 978-0-7623-1370-9.{{cite journal}}: CS1 maint: periodical has ISBN (link) Keen, Benjamin; Haynes, Keith (2012). A History of Latin America. Cengage Learning. ISBN 978-1-133-70932-9. Kennedy, Paul M. (1989). The Rise and Fall of the Great Powers: Economic Change and Military Conflict from 1500 to 2000. Vintage Books. ISBN 978-0-679-72019-5. Knight, Roger (2013). Britain Against Napoleon: The Organization of Victory, 1793–1815. Penguin UK. ISBN 978-0-14-197702-7. Leggiere, Michael V. (2014). Blücher: Scourge of Napoleon. University of Oklahoma Press. ISBN 978-0-8061-4567-9. Malia, Martin Edward (2006). History's Locomotives: Revolutions and the Making of the Modern World. Yale University Press. ISBN 978-0-300-12690-7. McConachy, Bruce (2001). "The Roots of Artillery Doctrine: Napoleonic Artillery Tactics Reconsidered".

Sources: en.wikipedia.org

Background from the literature

==== Gomori-positive astrocytes and brain dysfunction ==== A type of astrocyte with an aging-related pathology has been described over the last fifty years. Astrocytes of this subtype possess prominent cytoplasmic granules that are intensely stained by Gomori's chrome alum hematoxylin stain, and hence are termed Gomori-positive (GP) astrocytes. They can be found throughout the brain, but are by far the most abundant in the olfactory bulbs, medial habenula, dentate gyrus of the hippocampus, arcuate nucleus of the hypothalamus, and in the dorsal medulla, just beneath the area postrema. Gomori-positive cytoplasmic granules are derived from damaged mitochondria engulfed within lysosomes. Cytoplasmic granules contain undigested remnants of mitochondrial structures. These contents include heme-linked copper and iron atoms remaining from mitochondrial enzymes. These chemical substances account for the pseudoperoxidase activity of Gomori-positive granules that can utilized to stain for these granules. Oxidative stress is believed to be cause of damage to these astrocytes. However, the exact nature of this stress is uncertain. Brain regions enriched in Gomori-positive astrocytes also contain a sub-population of specialized astrocytes that synthesize Fatty Acid Binding Protein 7 (FABP7). Indeed, astrocytes in the hypothalamus that synthesize FABP7 have also been shown to possess Gomori-positive granules. Thus, a connection between these two glial features is apparent.

== History == The precise origin of absinthe is unclear. The medical use of wormwood dates back to ancient Egypt and is mentioned in the Ebers Papyrus from around 1550 BC. Wormwood extracts and wine-soaked wormwood leaves were used as remedies by the ancient Greeks. Moreover, some evidence exists of a wormwood-flavoured wine in ancient Greece called absinthites oinos. Lucretius' De Rerum Natura (I, 936–950) says that a drink containing wormwood was given as medicine to children in a cup with honey on the brim to make it drinkable. The first evidence of absinthe, in the sense of a distilled spirit containing green anise and fennel, dates to the 18th century. According to popular legend, it began as an all-purpose patent remedy created by Dr. Pierre Ordinaire, a French doctor living in Couvet, Switzerland, around 1792 (the exact date varies by account). Ordinaire's recipe was passed on to the Henriod sisters of Couvet, who sold it as a medicinal elixir. By other accounts, the Henriod sisters may have been making the elixir before Ordinaire's arrival. In either case, a certain Major Dubied acquired the formula from the sisters in 1797 and opened the first absinthe distillery named Dubied Père et Fils in Couvet with his son Marcellin and son-in-law Henry-Louis Pernod. In 1805, they built a second distillery in Pontarlier, France, under the company name Maison Pernod Fils. Pernod Fils remained one of the most popular brands of absinthe until the drink was banned in France in 1914.

=== Toxins === The leaves, stem, and green unripe fruit of the tomato plant contain small amounts of the alkaloid tomatine. They contain small amounts of solanine, a toxic alkaloid found in larger amounts in potato leaves and other members of the nightshade family. Tomato plants can be toxic to dogs if they eat large amounts of the fruit, or chew plant material. Small amounts of tomato foliage are sometimes used for flavoring, and the green fruit of unripe red tomato varieties is sometimes used for cooking, particularly as fried green tomatoes.

== History == Efficacy was evaluated in ARROS-1 (NCT05118789), a multi-center, single-arm, open-label, multi-cohort trial in participants with previously treated locally advanced or metastatic ROS1-positive NSCLC. The efficacy population included 117 participants; 59 who received one prior ROS1 tyrosine kinase inhibitor and 58 who received two or more prior ROS1 tyrosine kinase inhibitors, including lorlatinib, repotrectinib, and/or taletrectinib.

=== Progression === 30–40% of UCTD cases may develop into a defined connective tissue disease as more diagnostic criteria are progressively met. This generally happens within five years of onset. Several factors may help predict progression:

Sources: en.wikipedia.org

Frequently asked questions